Seeking Alpha

RedHill to receive $11.7M cash infusion

  • RedHill Biopharma (RDHL -0.4%) has entered into an agreement for an equity placement of $11.7M from Israeli institutional and private investors.
  • RedHill will use the money for R&D, including developing its RHB-104 treatment for Crohn's disease and RHB-105 for H. pylori infection, both of which are in Phase III studies, and for potential acquisitions. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: